Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 19:36:35时区推断·⟳ 抓取 19:37:43·⚡ 决策 08-03 19:45:09 +7m26s·84.9 天前
Medicus Pharma任命Faisal Mehmud为英国子公司Antev首席执行官
任命首席医学官兼任Antev CEO属于管理层安排，未披露临床读出、监管批准、融资或商业合同。
📄 原文Investing.com↗ 原文
Medicus Pharma names Faisal Mehmud CEO of UK subsidiary Antev
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks PHILADELPHIA - Medicus Pharma Ltd. (NASDAQ:MDCX…
不做 Medicus Pharma（MDCX.US）
管理层任命没有新增临床、监管或收入量级，不能形成事件交易，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 low · price-in 风险 medium ↗
关键理由
- 任命首席医学官兼任Antev CEO属于管理层安排，未披露临床读出、监管批准、融资或商业合同。
- MDCX.US报价0.2752美元，较前收上涨4.8%，但事件本身不改变Teverelix或SkinJect的可量化价值。
工具调用 · 历史记录,结果未知(5 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
- validate_order · 结果未知
原文全文
展开原文 · 2,028 字
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks
PHILADELPHIA - Medicus Pharma Ltd. (NASDAQ:MDCX) announced the appointment of Faisal Mehmud as Chief Executive Officer of Antev Limited, its United Kingdom subsidiary, effective August 30, according to a press release statement.
Dr. Mehmud will continue serving as Chief Medical Officer of Medicus and Co-Chairman of Antev while assuming the CEO role. He will oversee the development of Teverelix, a GnRH antagonist being developed for advanced prostate cancer, acute urinary retention and women’s health indications.
The appointment follows a planned transition period. Amit Kohli, who served as interim CEO of Antev since Medicus acquired the subsidiary on August 29, 2025, agreed at the time of acquisition to remain with the company for one year to facilitate the business transition.
Dr. Mehmud brings over 20 years of biopharmaceutical experience across clinical development, medical affairs, regulatory strategy and pharmacovigilance. He has held senior leadership positions at Pfizer, GSK, Bristol Myers Squibb, Novartis and Sanofi, where his responsibilities included global clinical development, medical affairs and regulatory strategy across multiple therapeutic areas.
"Since joining Medicus as Chief Medical Officer, Faisal has become an integral member of our executive leadership team," stated Dr. Raza Bokhari, Medicus Executive Chairman and CEO.
Dr. Mehmud earned his medical degree from the University of Cambridge and completed postgraduate training in Internal Medicine in the United Kingdom. He holds postgraduate qualifications in Internal Medicine and Pharmaceutical Medicine from the Royal College of Physicians.
Medicus Pharma is a biotech company focused on clinical development programs of therapeutic assets, including SkinJect for non-melanoma skin diseases and Teverelix for urologic and women’s health indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PHILADELPHIA - Medicus Pharma Ltd. (NASDAQ:MDCX) announced the appointment of Faisal Mehmud as Chief Executive Officer of Antev Limited, its United Kingdom subsidiary, effective August 30, according to a press release statement.
Dr. Mehmud will continue serving as Chief Medical Officer of Medicus and Co-Chairman of Antev while assuming the CEO role. He will oversee the development of Teverelix, a GnRH antagonist being developed for advanced prostate cancer, acute urinary retention and women’s health indications.
The appointment follows a planned transition period. Amit Kohli, who served as interim CEO of Antev since Medicus acquired the subsidiary on August 29, 2025, agreed at the time of acquisition to remain with the company for one year to facilitate the business transition.
Dr. Mehmud brings over 20 years of biopharmaceutical experience across clinical development, medical affairs, regulatory strategy and pharmacovigilance. He has held senior leadership positions at Pfizer, GSK, Bristol Myers Squibb, Novartis and Sanofi, where his responsibilities included global clinical development, medical affairs and regulatory strategy across multiple therapeutic areas.
"Since joining Medicus as Chief Medical Officer, Faisal has become an integral member of our executive leadership team," stated Dr. Raza Bokhari, Medicus Executive Chairman and CEO.
Dr. Mehmud earned his medical degree from the University of Cambridge and completed postgraduate training in Internal Medicine in the United Kingdom. He holds postgraduate qualifications in Internal Medicine and Pharmaceutical Medicine from the Royal College of Physicians.
Medicus Pharma is a biotech company focused on clinical development programs of therapeutic assets, including SkinJect for non-melanoma skin diseases and Teverelix for urologic and women’s health indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。